The ESG Weekly: Pipelines are OVER; and are drug prices too high?
A ruling by a US judge has put the entire oil and gas pipeline industry at risk in the US, and a lot of it is because companies have terrible community relations. And then, we discuss the price tag on Remdesivir, the first drug shown to be effective against the coronavirus \u2010 and how drug prices affect company incentives.